The goal of our laboratory is to identify genes that regulate cancer stem cell self-renewal, differentiation, and chemoresistance in the hematopoietic system using primary patient material as well as mouse model systems. We primarily focus on hematologic cancers that arise from hematopoietic stem/progenitors cells such as acute myeloid leukemia and the myelodysplastic syndromes and strive to develop improved methods to diagnose, monitor, and treat patients.


Please use this form to contact us.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Enter the characters shown in the image.
Continue Reading

Postdoctoral Position in the Erlebacher Lab

We are recruiting a postdoctoral fellow to work on mechanisms of systemic immune suppression during pregnancy and their application to the treatment of type 1 diabetes

Continue Reading

The Erlebacher lab receives a grant from the American Cancer Society

The Erlebacher lab receives a Research Scholars Grant from the ACS to study effector mechanisms of fetomaternal immune tolerance

Continue Reading

The Erlebacher Lab Publishes in the Journal of Experimental Medicine

We show the that antigens bound to follicular dendritic cells, a stromal cell type present within B cell follicles, are continuously sampled by lymph node-resident dendritic cells for presentation to CD8 T cells

Continue Reading
Subscribe to Christopher Park Lab RSS